ArticleInternational urology and nephrology2026
National penile cancer surgery centralisation in Ireland: five-year service performance, survival, and recurrence outcomes.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThe provision of penile cancer care in specialist centres decreases overtreatment and improves patient outcomes. Penile cancer care was centralised in the Republic of Ireland in 2021. We assess five-year service performance versus international standards, oncologic outcomes, and evaluate risk factors for disease recurrence.
methodsA retrospective analysis of prospectively collected data was performed. All patients undergoing penile cancer surgery at the National Penile Cancer Centre from January 2021 to July 2025 were included. Service metrics were compared against NHS and European Association of Urology standards. Overall survival (OS) was estimated by Kaplan-Meier. Multivariable logistic regression was carried out to assess factors associated with disease recurrence and mortality.
results151 patients were included. Phallus preservation was performed in 77% (n = 116). Centralisation met or approached most international targets, but timely multidisciplinary discussion lagged. Definitive treatment was received by 80% of patients (n = 121) within 62 days. Median OS was 58.7 months; 1 and 3-year disease-specific survival was 90% and 82%, respectively. Lymph node positivity (OR 8.29, 95% CI 2.01-34.3, p = 0.003), lymphovascular invasion (OR 4.58, 95% CI 1.48-14.22, p = 0.008) and perineural invasion (OR 5.83, 95% CI 1.84-18.51, p = 0.003) were associated with increased risk of mortality on univariate analysis. Local recurrence was 6% (n = 7) following organ-sparing surgery. Positive margins were significantly associated with higher recurrence risk on multivariate analysis (OR 3.20, 95% CI 1.02-10.04, p = 0.046).
conclusionCentralisation of penile cancer services has delivered high rates of organ preservation and guideline-concordant care. Gaps in multidisciplinary discussion and pathological reporting identify priorities for ongoing service improvement.
Indexed as
Identifiers
42873477What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.